The pausing defect could be rescued by upregulation of ARID1B, suggesting that both ARID1A and ARID1B control transcription via RNApol2 pausing and that dysregulated pausing likely mediates effects of ARID1A loss in cancers and possibly also neurodevelopmental disorders. This evidence concerns the gene ARID1A and cancer.